<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51805">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01696630</url>
  </required_header>
  <id_info>
    <org_study_id>XENON</org_study_id>
    <secondary_id>2012-002155-41</secondary_id>
    <secondary_id>ET2012-19</secondary_id>
    <nct_id>NCT01696630</nct_id>
  </id_info>
  <brief_title>A Study Which Compares the Efficacy of Xenon and Desflurane in Association With a Thoracic Epidural Analgesia</brief_title>
  <official_title>Phase II Study, Randomized, Monocentric, Single-blind, Comparing the Efficacy of Gases Xenon and Desflurane , in Association With a Thoracic Epidural Analgesia in Maintenance Phase of a Colorectal Oncologic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a monocentric study in 2 steps. First, there is a safety part to assess the
      feasibility of using Xenon in association with a thoracic epidural analgesia.

      A maximum of 9 patients will be enrolled in this first step. If the association is
      considered as safe, the second step will be initiated. This part will be randomized, simple
      blinded with 2 arms. 28 patients will be enrolled and will be followed during 45 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first step is divided into 3 parts. 9 patients will be sequentially enrolled (3 patients
      in each part).

      The patients will be followed during 45 days and the following rules will be used to assess
      the safety:

      First  part: if no toxicity: initiation of step 2. If 1/3 toxicity : start of the second
      part. If 2 or 3/3 toxicity : end of the study Second part: same rules and possible start of
      the third part. Third part: if no toxicity: initiation of step 2. If 1 or more toxicity :
      end of the study.

      The safety will be assessed after each part by an independent data safety monitoring board.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Assess the fluctuation of peroperative mean Arterial Pressure</measure>
    <time_frame>during the whole maintenance phase, an expected average of 6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The initial value (taken just before anesthesia induction) will be compared to the lowest value of mean Arterial Pressure observed during the whole maintenance phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of Systolic ejection volume</measure>
    <time_frame>All along the maintenance of anesthesia, an expected average of 6 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the number of days including the surgery date and the discharge date</measure>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the number of minutes between the end of surgery and postoperative room exit</measure>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the total dose administered of vasopressive and hypotensive agents</measure>
    <time_frame>All along the maintenance of anesthesia, an expected average of 6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>in mg/Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the volume of each product administered for hydration</measure>
    <time_frame>All along the maintenance of anesthesia, an expected average of 6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>in mL/Kg/hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the total dose of morphinics</measure>
    <time_frame>All along the maintenance of anesthesia, an expected average of 6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>required to maintain BIS between 40 and 60 (in mg/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Aldrete score and Recovery Index</measure>
    <time_frame>5 minutes after eyes opening</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the number of days until an oral feeding</measure>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with Adverse Events as a Measure of Safety</measure>
    <time_frame>45 days after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>according to the NCI-CTC version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Score to Visual analog scale for pain</measure>
    <time_frame>At entrance and exit of post operative room and 24 hours after the end of anesthesia</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of corrected ejection time</measure>
    <time_frame>All along the maintenance of anesthesia, an expected average of 6 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of heart rate</measure>
    <time_frame>All along the maintenance of anesthesia, an expected average of 6 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the delay of bowel movement recovery</measure>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Desflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Desflurane 6.5% (+/-0.5%) in association with a thoracic epidural analgesia in maintenance phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xenon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xenon 60% (+/-5%) in association with a thoracic epidural analgesia in maintenance phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenon</intervention_name>
    <arm_group_label>Xenon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <arm_group_label>Desflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years old

          -  Planned surgery for oncologic colic and/or rectal surgery

          -  ASA score I or II

          -  Indication of complementary thoracic epidural analgesia

          -  Agree to use an effective form of contraception

          -  Patients who can understand, read and write French language

          -  Covered by a medical insurance

          -  Patients who have dated/signed an inform consent

        Exclusion Criteria:

          -  Unstable angina within the 30 last days

          -  Myocardial infarction within 28 days prior to surgery

          -  Uncontrolled arterial high blood pressure

          -  Severe cardiac insufficiency

          -  Severe chronic obstructive pneumopathy

          -  Patient who requires FiO2 &gt; 40%

          -  Patient already enrolled in a clinical study which may interfere with the present
             study

          -  Known hypersensitivity to one of the study drugs

          -  History or familial history of malignant hyperthermia

          -  Documented high intracranial pressure

          -  Eclampsia or pre-eclampsia

          -  Pregnant or breastfeeding woman

          -  Liver injury (icterus) and/or unexplained fever and/or eosinophilia after halogen
             exposure

          -  Failure in epidural anesthesia installation

          -  Patient refusal

          -  Patient who can't be compliant to the present protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julien GAUTIER</last_name>
    <phone>+33 4 26 55 68 29</phone>
    <email>julien.gautier@lyon.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie FOUILLAT</last_name>
    <phone>+33 4 78 78 79 39</phone>
    <email>valerie.fouillat@lyon.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>LYON Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georges ROMERO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edouard AUBERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick BACHMANN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri-Jacques CLEMENT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Laure DAUNIZEAU-WALKER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Baptiste VALLEIX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Edgard MAZERES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabienne MONTANGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique PERES-BACHELOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie POUDEROUX-MARTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hervé ROSAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri SEBBAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Nakata Y, Goto T, Ishiguro Y, Terui K, Kawakami H, Santo M, Niimi Y, Morita S. Minimum alveolar concentration (MAC) of xenon with sevoflurane in humans. Anesthesiology. 2001 Apr;94(4):611-4.</citation>
    <PMID>11379681</PMID>
  </reference>
  <reference>
    <citation>Rasmussen LS, Schmehl W, Jakobsson J. Comparison of xenon with propofol for supplementary general anaesthesia for knee replacement: a randomized study. Br J Anaesth. 2006 Aug;97(2):154-9. Epub 2006 Jun 17.</citation>
    <PMID>16782975</PMID>
  </reference>
  <reference>
    <citation>Salmi E, Laitio RM, Aalto S, Maksimow AT, Långsjö JW, Kaisti KK, Aantaa R, Oikonen V, Metsähonkala L, Någren K, Korpi ER, Scheinin H. Xenon does not affect gamma-aminobutyric acid type A receptor binding in humans. Anesth Analg. 2008 Jan;106(1):129-34, table of contents.</citation>
    <PMID>18165567</PMID>
  </reference>
  <reference>
    <citation>CULLEN SC, GROSS EG. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science. 1951 May 18;113(2942):580-2.</citation>
    <PMID>14834873</PMID>
  </reference>
  <reference>
    <citation>Wappler F, Rossaint R, Baumert J, Scholz J, Tonner PH, van Aken H, Berendes E, Klein J, Gommers D, Hammerle A, Franke A, Hofmann T, Schulte Esch J; Xenon Multicenter Study Research Group. Multicenter randomized comparison of xenon and isoflurane on left ventricular function in patients undergoing elective surgery. Anesthesiology. 2007 Mar;106(3):463-71.</citation>
    <PMID>17325504</PMID>
  </reference>
  <reference>
    <citation>Baumert JH, Hein M, Hecker KE, Satlow S, Schnoor J, Rossaint R. Autonomic cardiac control with xenon anaesthesia in patients at cardiovascular risk. Br J Anaesth. 2007 Jun;98(6):722-7. Epub 2007 Apr 27.</citation>
    <PMID>17468494</PMID>
  </reference>
  <reference>
    <citation>Luttropp HH, Thomasson R, Dahm S, Persson J, Werner O. Clinical experience with minimal flow xenon anesthesia. Acta Anaesthesiol Scand. 1994 Feb;38(2):121-5.</citation>
    <PMID>7909641</PMID>
  </reference>
  <reference>
    <citation>Rossaint R, Reyle-Hahn M, Schulte Am Esch J, Scholz J, Scherpereel P, Vallet B, Giunta F, Del Turco M, Erdmann W, Tenbrinck R, Hammerle AF, Nagele P; Xenon Study Group. Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. Anesthesiology. 2003 Jan;98(1):6-13.</citation>
    <PMID>12502972</PMID>
  </reference>
  <reference>
    <citation>Dupont J, Tavernier B, Ghosez Y, Durinck L, Thevenot A, Moktadir-Chalons N, Ruyffelaere-Moises L, Declerck N, Scherpereel P. Recovery after anaesthesia for pulmonary surgery: desflurane, sevoflurane and isoflurane. Br J Anaesth. 1999 Mar;82(3):355-9.</citation>
    <PMID>10434815</PMID>
  </reference>
  <reference>
    <citation>Stuttmann R, Jakubetz J, Schultz K, Schäfer C, Langer S, Ullmann U, Hilbert P. Recovery index, attentiveness and state of memory after xenon or isoflurane anaesthesia: a randomized controlled trial. BMC Anesthesiol. 2010 May 7;10:5. doi: 10.1186/1471-2253-10-5.</citation>
    <PMID>20459661</PMID>
  </reference>
  <reference>
    <citation>Diemunsch P; Société française d'anesthésie et de réanimation. [Conference of experts--short text. Management of postoperative nausea and vomiting. French Society of Anesthesia and Resuscitation]. Ann Fr Anesth Reanim. 2008 Oct;27(10):866-78. Epub 2008 Oct 25. French.</citation>
    <PMID>18952398</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 16, 2013</lastchanged_date>
  <firstreceived_date>September 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>maintenance of anesthesia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Xenon</mesh_term>
    <mesh_term>Desflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
